TOP STORY
Annual global spending on medicines will reach nearly $1.2 trillion by 2016, while U.S. spending growth is projected to soar to between $350 and $380 billion by 2016, according to a report issued recently by the IMS Institute for Healthcare Informatics. » More |
CONTINUING EDUCATION
Pharmacists need to gain insight into cultural competency to better serve the increasing racial and ethnic populations in the United States.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
ADVERTISEMENT
New Drug Price Type Options:
 White Paper
Two new and different methods to ascertain true drug acquisition cost can save money on Rx drug benefits. Read white paper for details and comparison of NADAC and PAC. |
EDITOR’S PICK
New models support comparative research, more nonprescription drugs
The drive for personalized medicine and greater patient involvement in treatment decisions demands more informative data on the effects and risks associated with drugs and medical products. » Click here. |
CLINICAL NEWS
Comorbidity from chronic diseases and severity of illness increased the likelihood of adverse drug reactions in senior patients, according to a new study published online June 26 in the Annals of Pharmacotherapy. » More |
|
A fixed-dose combination of azilsartan medoxomil and chlorthalidone 40/25 mg (Edarbyclor, Takeda Pharmaceuticals) was statistically superior to a fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide 40/25 mg for the treatment of stage 2 systolic hypertension, according to a study published online in the American Heart Association journal Hypertension. » More |
|
FDA issued a statement reminding healthcare professionals about the need to adjust the dosage of the antibacterial drug cefepime (Maxipime, Elan) in patients with renal impairment. » More |
Survey
a) "Lock-in" programs – limiting access for high utilizers to single pharmacy and/or physician provider
b) Tighter dispensing limits on the number of units and/or prescriptions a patient can receive for controlled meds
c) Limiting coverage to only long-acting formulations with effective abuse-deterrant delivery systems
d) More broad and advanced state-based controlled prescription monitoring/surveillance systems
e) Limiting coverage of long-acting opioid prescriptions to select specialty providers
f) Other
Click here and see what your colleagues think, too.
Want to see the results of our last survey about specialty pharmacy services? Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
